Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabergoline versus Sandostatin LAR plus cabergoline for nonfunctional pituitary adenoma
IRCT20171003036521N2Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Apr 2018
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in pituitary adenoma comparing Cabergoline with Sandostatin LAR + cabergoline (2 arms). Primary endpoints: Tumor volume reduction after surgery, Visual field improvement and 3 more. Started Apr 2018; status: completed.
02
Drugs
cabergolineoctreotide
03
Conditions
pituitary adenoma
Beyond the preview
Go deeper on IRCT20171003036521N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20171003036521N2.